Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley sold 2,000 shares of Illumina stock in a transaction dated Thursday, October 26th. The shares were sold at an average price of $206.88, for a total transaction of $413,760.00. Following the sale, the executive vice president now owns 34,579 shares in the company, valued at $7,153,703.52. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Marc Stapley also recently made the following trade(s):

  • On Tuesday, September 5th, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $205.93, for a total transaction of $411,860.00.
  • On Thursday, August 3rd, Marc Stapley sold 2,000 shares of Illumina stock. The shares were sold at an average price of $196.80, for a total transaction of $393,600.00.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded down 2.97% on Monday, reaching $203.81. 671,916 shares of the company traded hands. Illumina, Inc. has a one year low of $119.37 and a one year high of $214.50. The company has a market capitalization of $29.76 billion, a PE ratio of 40.89 and a beta of 0.76. The firm has a 50-day moving average price of $205.96 and a 200 day moving average price of $188.35.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The business’s revenue for the quarter was up 17.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.97 EPS. Equities analysts forecast that Illumina, Inc. will post $3.73 EPS for the current fiscal year.

WARNING: This piece was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was copied illegally and republished in violation of U.S. & international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/30/insider-selling-illumina-inc-ilmn-evp-sells-2000-shares-of-stock.html.

Several analysts have recently weighed in on ILMN shares. Barclays PLC lifted their target price on shares of Illumina from $150.00 to $185.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 25th. Zacks Investment Research raised shares of Illumina from a “hold” rating to a “buy” rating and set a $229.00 price target for the company in a report on Friday. Canaccord Genuity reissued a “buy” rating and set a $230.00 price target (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. BidaskClub downgraded shares of Illumina from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies reissued an “overweight” rating and set a $226.00 price target (up from $202.00) on shares of Illumina in a report on Monday, October 9th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $200.88.

Institutional investors and hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC boosted its holdings in Illumina by 13.0% during the 2nd quarter. Advisory Services Network LLC now owns 772 shares of the life sciences company’s stock worth $134,000 after acquiring an additional 89 shares during the last quarter. Penserra Capital Management LLC boosted its holdings in Illumina by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock worth $153,000 after acquiring an additional 102 shares during the last quarter. Paradigm Asset Management Co. LLC boosted its holdings in Illumina by 5.6% during the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after acquiring an additional 50 shares during the last quarter. NN Investment Partners Holdings N.V. boosted its holdings in Illumina by 11.3% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 985 shares of the life sciences company’s stock worth $171,000 after acquiring an additional 100 shares during the last quarter. Finally, Elefante Mark B boosted its holdings in Illumina by 3.7% during the 2nd quarter. Elefante Mark B now owns 1,253 shares of the life sciences company’s stock worth $218,000 after acquiring an additional 45 shares during the last quarter. 93.04% of the stock is currently owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.